A group of plaintiffs who sued Johnson & Johnson‘s (NYSE:JNJ) DePuy Orthopaedics in a bellwether case over alleged defects associated with its Pinnacle metal-on-metal hips are looking for approximately $246.1 million in damages, according to recently released court documents.
The damages come after a jury in Texas federal court ruled in favor of the plaintiffs, finding J&J liable for the defects and fraud.
Plaintiff Michael Stevens is seeking a total of approximately $37.8 million, Euegen Stevens is seeking approximately $36.8 million, Hazel Miura is seeking approximately $43.7 million, Karen Krischner is seeking approximately $48.6 million, Uriel Barzel is seeking approximately $39.4 million and Ramon Alicea is seeking approximately $39.8 million, according to court documents.
The amount is approximately $1 million lower than the $247 million in damages initially listed in the ruling released last November.
In November, the jury ruled that the controversial metal-on-metal hip implants were defectively designed and that patients did not receive appropriate warning about the risks associated with them, according to the report.
The six plaintiffs and patients in the case claimed that after implantation, the devices led to injuries including tissue death, bone erosion and other negative health effects, according to Reuters.
In the case, plaintiffs said that the companies falsely promoted the device with claims that it would last longer than more basic implants which featured plastic or ceramic materials.
The verdict is the fourth test trial in Dallas federal court over the metal-on-metal Pinnacle hips, with over 9,000 cases pending.
In December 2016, a federal jury in Dallas ordered J&J and DePuy Orthopedics to pay more than $1 billion to 6 plaintiffs claiming to be injured by its Pinnacle metal-on-metal hip implants, according to the plaintiffs lawyers.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.